why choose us

First received: August 17, 2023

Clinical Trial: Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Locally Advanced Adrenal Cortex Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Atezolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma

Brief Summary: This phase II trial tests how well cabozantinib in combination with atezolizumab works in treating patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable).Cabozantinib inhibits receptor tyrosine kinases, which are receptors commonly over-expressed by tumor cells.This may result in an inhibition of both tumor growth…

Read more